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Abstract
Introduction The short-term mortality benefit of lower tidal
volume ventilation (LTVV) for patients with acute lung injury/
acute respiratory distress syndrome (ALI/ARDS) has been
demonstrated in a large, multi-center randomized trial. However,
the impact of LTVV and other critical care therapies on the
longer-term outcomes of ALI/ARDS survivors remains uncertain.
The Improving Care of ALI Patients (ICAP) study is a multi-site,
prospective cohort study that aims to evaluate the longer-term
outcomes of ALI/ARDS survivors with a particular focus on the
effect of LTVV and other critical care therapies.
Methods Consecutive mechanically ventilated ALI/ARDS
patients from 11 intensive care units (ICUs) at four hospitals in
the city of Baltimore, MD, USA, will be enrolled in a prospective
cohort study. Exposures (patient-based, clinical management,
and ICU organizational) will be comprehensively collected both
at baseline and throughout patients' ICU stay. Outcomes,
including mortality, organ impairment, functional status, and
quality of life, will be assessed with the use of standardized
surveys and testing at 3, 6, 12, and 24 months after ALI/ARDS
diagnosis. A multi-faceted retention strategy will be used to
minimize participant loss to follow-up.
Results On the basis of the historical incidence of ALI/ARDS at
the study sites, we expect to enroll 520 patients over two years.
This projected sample size is more than double that of any
published study of long-term outcomes in ALI/ARDS survivors,
providing 86% power to detect a relative mortality hazard of
0.70 in patients receiving higher versus lower exposure to LTVV.
The projected sample size also provides sufficient power to
evaluate the association between a variety of other exposure
and outcome variables, including quality of life.
Conclusion The ICAP study is a novel, prospective cohort study
that will build on previous critical care research to improve our
understanding of the longer-term impact of ALI/ARDS, LTVV
and other aspects of critical care management. Given the
paucity of information about the impact of interventions on long-
term outcomes for survivors of critical illness, this study can
provide important information to inform clinical practice.Page 1 of 11
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Acute lung injury and acute respiratory distress syndrome
(ALI/ARDS) are common causes of morbidity and mortality in
critically ill patients. Improvements in critical care practice,
including changes in mechanical ventilation strategies, have
decreased short-term mortality rates for ALI/ARDS patients
[1]. As a consequence, the longer-term outcomes of ALI/
ARDS survivors have become a research priority [2,3]. For
example, although lower tidal volume ventilation (LTVV) has
been shown to reduce short-term mortality [4], its impact on
patients' longer-term functional status and quality of life
remains uncertain. An improved understanding of long-term
patient outcomes may lead to important changes in critical
care practice [5,6].
Most studies of long-term outcomes in ALI/ARDS survivors
have recruited relatively small numbers of patients and have
not investigated the effects of specific critical care interven-
tions. For example, of at least 13 independent studies that
investigated quality of life (QOL) outcomes in ARDS patients
[7] (DW Dowdy, MP Eid, CR Dennison, PA Mendez-Tellez,
MS Herridge, E Guallar, PJ Pronovost and DM Needham,
unpublished work), none had a sample size of more than 83
survivors [8], and only two studies (with sample sizes of 66 [9]
and 20 [10]) evaluated the impact of a specific critical care
intervention on QOL. Furthermore, none of the five randomized
trials of LTVV included an assessment of long-term QOL or
other outcomes in their original study design [11]. Thus, the
magnitude of improvement in long-term, patient-centered out-
comes resulting from the use of many specific intensive care
unit (ICU) therapies (e.g. LTVV) remains uncertain. Further-
more, the mechanisms through which these therapies may
affect patient outcomes require further investigation [12].
To help to address these issues, the Improving Care of ALI
Patients (ICAP) study was created. The ICAP study is a multi-
site, prospective cohort study designed to evaluate the asso-
ciations of ALI/ARDS, LTVV, and other aspects of critical care
with 2-year outcomes.
Methods
Using a prospective cohort study design, the ICAP study will
enroll consecutive patients with ALI/ARDS from 11 intensive
care units (four medical, five surgical, and two trauma) at four
teaching hospitals in the city of Baltimore, MD, USA. These
participants will be evaluated in hospital and their outcomes
will be assessed during follow-up at 3, 6, 12, and 24 months
after ALI/ARDS diagnosis. Figure 1 provides a timeline of par-
ticipants' clinical course and the study-related assessments.
Inclusion criteria
To be eligible for enrollment in the ICAP study, participants
must be mechanically ventilated and meet criteria for the diag-
nosis of ALI/ARDS, as defined by the American-European
Consensus Conference [13].
Exclusion criteria
Patients are excluded if they meet any of the following eight
criteria:
1. More than 96 hours between ALI/ARDS diagnosis and
enrollment.
2. More than five days of mechanical ventilation during the
present hospitalization before enrollment.
3. Pre-existing ALI/ARDS when transferred to a study ICU.
4. Pre-existing illness with a life expectancy of less than six
months.
5. Any limitation of care at the time of enrollment (for example
no cardiopulmonary resuscitation).
6. Previous lung resection.
7. Inability to speak or understand English.
8. No fixed address.
These criteria exclude patients with substantial exposure to
critical care before enrollment (exclusion criteria 1, 2, and 3),
Figure 1
Timeline for the Improving Care of ALI Patients (ICAP) study. ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ICU, intensive care 
unit.Page 2 of 11
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sion criteria 4 and 5), or significant barriers to prescribed out-
come evaluations (exclusion criteria 6, 7, and 8).
Exposure assessment
Exposures assessed in the ICAP study fall into three major cat-
egories: patient-based, clinical management, and ICU organi-
zational exposures (Table 1) [14]. Patient-based exposures
assessed at the time of study enrollment include demograph-
ics, comorbidities, admission diagnosis, severity of illness, and
medications taken before hospitalization. Pilot testing indi-
cates that medical chart abstraction for one-time measure-
ment of these exposures takes about 30 minutes.
Patient-based and clinical management exposures measured
while the participant is in the ICU vary over time, so the expo-
sure measurements must account for this time-dependent
course of critical care after ALI/ARDS diagnosis. Of particular
importance, given the study objectives, are the participants'
mechanical ventilator settings (for example. tidal volume and
pressures) and associated arterial blood gas values. These
important time-varying exposures are measured with the great-
est frequency (twice daily). Other patient-based and clinical
management exposures are measured once daily. On the
basis of pilot testing, the time required for daily collection of
these exposures is about 45 minutes per patient-day (Table 1).
ICU organizational exposures measured in the ICAP study
include staff:patient ratios, ICU occupancy, and use of proto-
cols for specific ICU therapies (for example. LTVV and
intensive insulin therapy [15]). Although infrequently consid-
ered in previous studies [16], recent research has demon-
strated that ICU organizational exposures have an important
impact on short-term patient outcomes [17-19]. Thus, pro-
spective measurement of these variables and their association
with long-term patient outcomes has the potential to inform
clinical practice. Because some of these ICU organizational
exposures vary less frequently than other exposures, they are
measured twice weekly.
When available, existing validated measurement instruments
are used for exposure assessment. The Acute Physiology and
Chronic Health Evaluation (APACHE) II system, Sequential
Organ Failure Assessment (SOFA) score, and Charlson
Table 1
Exposures assessed in the Improving Care of ALI Patients (ICAP) study
Exposure Instrument Data source Time(s) of assessment Time requireda (minutes)
Patient-based exposures
Demographics, baseline medicationsb, ICU/
hospital admitting diagnosis
Custom-made Chart review Enrollment 18
Comorbidities Charlson Index [21] Chart review Enrollment 5
Severity of illness APACHE II [20] Chart review Enrollment 7
SOFA [22] Chart review ICU stay (daily) 3
Sedation RASS [23,24] Patient exam ICU stay (daily) <1
Delirium CAM-ICU [25] Patient exam ICU stay (daily) 1
Laboratory valuesc Custom-made Chart review ICU stay (daily) 3
Clinical management exposures
Use of lower tidal volume ventilation Custom-made Chart review ICU stay (twice daily) 14
Medicationsb, physical and occupational 
therapy
Custom-made Chart review ICU stay (daily); discharge 15
Tracheotomy timing, dialysis, blood products, 
nutritional support
Custom-made Chart review ICU stay (daily) 8
ICU organizational exposures
Staff:patient ratio Custom-made Nurse and RT ICU stay (twice weekly) 3
ICU occupancy Custom-made Charge nurse ICU stay (twice weekly) 3
Use of treatment protocols Custom-made Chart review ICU stay (daily) 1
ALI, acute lung injury; APACHE, Acute Physiology and Chronic Health Evaluation; CAM-ICU, Confusion Assessment Method for the ICU; ICU, 
intensive care unit; RASS, Richmond Agitation–Sedation Scale; RT, respiratory therapist; SOFA, Sequential Organ Failure Assessment.
aDerived from pilot testing. The total time for assessment at enrollment is 30 minutes and for daily ICU data collection is 45 minutes per patient. 
bIncludes anti-psychotics, sedatives, narcotics, steroids, insulin, oral hypoglycemics, diuretics, erythropoietin, iron/vitamins. For the in-patient 
portion of the study, data are also collected on neuromuscular blockers, specific antibiotics and antifungals, and activated protein C [52]. c 
Includes blood sugar (measured twice daily, as well as daily minimum and maximum); lowest daily hemoglobin, platelet count, and albumin; highest 
daily creatinine and creatine kinase.Page 3 of 11
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tality and other outcomes in ICU patients [20-22]. Similarly,
validity and reliability have been demonstrated for the Rich-
mond Agitation–Sedation Scale (RASS) [23,24] and the Con-
fusion Assessment Method for the ICU (CAM-ICU) [25] as
measures of sedation and delirium, respectively, among ICU
patients. Delirium, measured with the CAM-ICU, is an impor-
tant independent predictor of mortality in mechanically venti-
lated patients [26].
Outcome assessment: baseline measurements
Poor long-term outcomes in ALI/ARDS survivors may reflect
either pre-existing morbidity or persistent effects of critical ill-
ness and/or ICU treatments. For example, three studies that
retrospectively measured baseline QOL in critically ill patients
found significant global decrements in QOL when compared
with population norms [27-29]. Thus, long-term QOL decre-
ments in ICU survivors (in comparison with population norms)
probably reflect both poor baseline status and potential
adverse effects of critical illness. To understand the relative
contributions of these factors, patients' baseline status before
hospitalization must be assessed and compared with their sta-
tus at follow-up.
Because ALI/ARDS patients are admitted to the ICU under
emergent conditions, their ideal baseline (for example, pre-
admission) status is difficult, if not impossible, to obtain. Con-
sequently, most studies of ICU survivors do not control for
baseline status when measuring outcomes during follow-up
[16]. To help in addressing this methodological issue, the
ICAP study will use standardized surveys for the retrospective
estimation of baseline QOL, physical functional status, and
hearing handicap in patients surviving their ICU stay (Table 2).
Pilot tests indicate that administration of these retrospective
surveys takes about 60 minutes per participant (Table 2), more
than double the time required for survey administration during
follow-up. This additional time results from fatigue, inattention,
and interruptions related to medical care while administering
these surveys on the hospital ward.
Participants' retrospective report of their baseline status may
be influenced by their current status at the time of this assess-
ment, leading to recall bias in the baseline measurement. Thus,
the ICAP study will explore patient proxies as an alternative
method of estimating baseline status. In a subgroup of con-
secutive consenting participants, close contacts will be identi-
fied and asked to complete the same baseline surveys that
were completed by patients. Proxy responses will then be
compared with those of the participants to assess the overall
level of agreement and any systematic differences between
the two response groups. Understanding differences between
participant and proxy-based assessments will enable investi-
gators to adjust for any systematic differences in proxy
responses obtained during follow-up when participants are
not available for direct assessment (for example, owing to hos-
pitalization, impaired physical or mental condition, or
incarceration).
Outcome assessment: follow-up
Outcomes assessed in the ICAP study include mortality and
medical outcomes, organ impairment, functional status, and
quality of life (Table 3). Outcomes are assessed at 3, 6, 12,
and 24 months after ALI/ARDS diagnosis in a research clinic
staffed by trained research assistants, nutritionists, and physi-
cal therapists. When patients are unable to attend their clinic
appointment, visits to their home or rehabilitation facility or tel-
ephone interviews will be conducted. Each follow-up visit
requires about four hours (Table 3).
Outcomes are assessed with standardized instruments, most
of which are used widely in critical care research [30]. Some
instruments, such as the Medical Outcomes Study Short Form
36-Item Health Survey (SF-36) [31], have been specifically
validated in critically ill populations, whereas others (for
example, the EuroQOL (EQ-5D) [32], Activities of Daily Living
(ADL) [33], and Instrumental Activities of Daily Living (IADL)
[34] surveys) have been validated only in more general patient
populations. Because certain issues being explored within the
ICAP study have not been widely investigated in critically ill
patients, these assessments will require instruments validated
predominantly in non-ICU patient populations. For example,
the ICAP study is the first large study to measure long-term
swallowing impairment and hearing handicap among ICU sur-
vivors. Corresponding instruments (for example, Sidney Swal-
lowing Questionnaire and Hearing Handicap Inventory for
Adults – Screener) were selected on the basis of validation
studies completed in other patient populations [35,36].
Table 2
Outcomes retrospectively assessed at baseline in the 
Improving Care of ALI Patients (ICAP) study
Outcome Instrument(s) Time required 
(minutes)
Hearing HHIA-S survey [36] 4
Physical functional 
status
ADL survey [33] 6
IADL survey [34] 8
Employment, 





EQ-5D survey [32] 4
SF-36 survey [53] 24
ADL, Activities of Daily Living; ALI, acute lung injury; EQ-5D, 
EuroQOL; HHIA-S, Hearing Handicap Inventory for Adults – 
Screening; IADL, Instrumental Activities of Daily Living; SF-36, 
Medical Outcomes Study Short Form 36-Item Health Survey. The 
time required is derived from pilot testing. The total time for baseline 
assessment is at least 60 minutes per patient.Page 4 of 11
(page number not for citation purposes)
Available online http://ccforum.com/content/10/1/R9Quality assurance over data collection
The ICAP study collects a large amount of data regarding
patient exposures and outcomes. To reduce measurement
error, a comprehensive data quality assurance program will be
employed. As outlined in Table 4, this program includes sev-
eral components: first, a comprehensive training, certification
and ongoing quality assurance review of study coordinators;
second, duplicate data entry with extensive validity checks
conducted by the data entry staff and database software; and
third, regular review of the entire database, by means of cus-
tomized descriptive statistics algorithms, to assess potential
outlier, illogical and missing data values. This multi-faceted
approach will help to ensure the accuracy of data in the ICAP
study.
Informed consent in critically ill patients
While in the ICU, most eligible patients cannot provide
informed consent to participate in the ICAP study because of
sedation, delirium, or physical or emotional distress. Further-
more, pilot testing of the ICAP study protocol revealed that
patient proxies are frequently not available on a timely basis.
Delays in obtaining consent impede the accurate assessment
of patient exposures that cannot be obtained retrospectively
(for example, sedation and delirium status). Thus, to facilitate
prompt participant enrollment without biasing the study sam-
ple against patients without readily available proxies, a waiver
of consent was requested from the Institutional Review Board
of each participating site. Because the study protocol poses
minimal risk to patients, this waiver request was approved,
thus allowing observational data to be collected, without con-
Table 3
Outcomes assessed during follow-up in the Improving Care of ALI Patients (ICAP) study
Outcome Instrument(s) Time requireda (minutes)
Medical outcomes
Survival
New medical diagnoses and ICU sequelae Custom-made survey 4
Impairment and disability
Hearing HHIA-S survey [36] 2
Swallowing SSQ survey [35] 5
Nutritional status Physical examb and custom-made surveyc 5
Pulmonary function PFTd 95
Functional status
Physical function Physical exame 20
ADL survey [33] 2
IADL survey [34] 2
Six-minute walk distance [54] 20
Mental function (stress, anxiety and 
depression)
IES-R survey [55] 5
HAD survey [56] 6
Cognitive function TICS-M survey [57] 5
Recovery/return to work Custom-made survey 5
Quality of life
Health-related quality of life EQ-5D survey [32] 2
SF-36 survey [53] 12
ADL, Activities of Daily Living; ALI, acute lung injury; EQ-5D, EuroQOL; HAD, Hospital Anxiety and Depression; HHIA-S, Hearing Handicap 
Inventory for Adults – Screening; IADL, Instrumental Activities of Daily Living; ICU, intensive care unit; IES-R, Impact of Event Scale – Revised; 
PFT, Pulmonary Function Tests; SF-36, Medical Outcomes Study Short Form 36-Item Health Survey; SSQ, Sidney Swallowing Questionnaire; 
TICS-M, Telephone Interview of Cognitive Status – Modified.
aDerived from pilot testing. Total time for outcome assessment is about 4 hours per participant, including a total of 50 minutes for transportation of 
participant between the hospital entrance, research clinic, physical therapy area and PFT laboratory within the hospital buildings. All outcomes are 
assessed at 3, 6, 12, and 24 months after acute lung injury/acute respiratory distress syndrome diagnosis unless otherwise noted. bIncludes body 
weight, triceps skin fold thickness, and mid-arm muscle circumference. cIncludes a selection of questions adapted from the Subjective Global 
Assessment [58]. dIncludes maximal inspiratory pressure (15 minutes to complete), spirometry (20 minutes), diffusion capacity for carbon 
monoxide (DLCO) with single-breath total lung capacity (TLC) (60 minutes, including wait time at the PFT laboratory). Spirometry, DLCO and TLC 
are not performed at the 6-month follow-up. eIncludes hand-grip dynamometry and manual muscle strength testing.Page 5 of 11
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who survive their ICU stay are then asked for consent to par-
ticipate in the long-term follow-up portion of the study.
Participant retention strategies
An important challenge facing longitudinal research in ICU sur-
vivors is the threat of selection bias from loss to follow-up. Par-
ticipants who are lost to follow-up may not be representative
of the original study sample as a result of increased morbidity
(hindering appointment attendance) or improved outcomes
(increasing mobility and capacity to move to distant locations)
[14]. Thus, participant retention strategies will have a vital role
in the success of the ICAP study (Table 5). Retention efforts
will begin immediately once eligible patients have consented
and will continue for the duration of the study, using frequent
telephone, written, and in-person communication with each
participant. For purposes of scheduling follow-up appoint-
ments, participants will be actively tracked with the following
sequence of events: three telephone calls to the primary con-
tact number; telephone calls to alternative numbers; signature-
required/registered letters; telephone calls and letters to alter-
nate contacts; local and online telephone directory searches;
unscheduled home visits; and confirmation of vital status from
government databases. The proportion of patients contacted
and the number of visits scheduled and completed will be
reviewed on a weekly basis to track the implementation and
performance of the retention strategies.
Analysis
The primary statistical analysis for the ICAP study will assess
the casual effect of LTVV on patient mortality. Exposure to
LTVV will be evaluated with a compliance algorithm from a
related randomized trial [4]. This analysis is complex because
within the observational study design, the primary exposure
(for example, LTVV) is 'time-dependent' and 'dynamic', mean-
ing that the exposure varies over time and depends on a
Table 4
Quality assurance program for the Improving Care of ALI Patients (ICAP) study
1. Quality assurance at data collection
a. Initial training of new study coordinators
i. Written Operations Manual as a reference source for standardized in-patient and out-patient data collection (more than 200 pages)
ii. Comprehensive group training sessions, including review of the Operations Manual, and demonstration and supervised completion of 
relevant assessment techniques
iii. Individual training sessions for data abstraction methods for paper-based and electronic-based ICU charting systems, and for out-patient 
interviews and assessments
b. Certification of study coordinators for independent data collection
i. Use of standardized quality assurance data collection instruments to re-abstract pertinent data for the first three study participants of each 
in-patient study coordinator. Accuracy of at least 95% is required for a study coordinator to be certified for ongoing independent data 
collection
ii. Supervision of completion of patient surveys and assessments for new out-patient study staff. Demonstration of adherence to study 
protocol is required before independent data collection
c. Ongoing quality assurance
i. Monthly, in-person meetings of all in-patient study and out-patient study coordinators to review data collection questions and quality 
assurance concerns
ii. Regular e-mail reminders clarifying any data collection guidelines
iii. Ongoing, random quality assurance reviews as described in (b) above
2. Quality assurance at data entry
a. Manual review of all data collection forms for missing and potentially inaccurate data by data entry staff with follow-up of questionable data 
items by lead study coordinator
b. Automated data entry validity checks by database software using predefined parameters for each specific data item
c. Independent duplicate data entry with reconciliation of any differences
3. Quality assurance after data entry
a. Ongoing and regular review of a customized set of descriptive statistics for all data in the database to identify potentially missing, outlier and 
illogical data items. All identified items are individual checked by study coordinators and any systematic problems are relayed to study 
coordinators for corrective measures
ALI, acute lung injury; ICU, intensive care unit.Page 6 of 11
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pital, and receiving mechanical ventilation), which also
changes during the study period. Appropriate statistical meth-
ods for the causal analysis of such time-varying, dynamic treat-
ment regimes have been developed recently [37]. These
methods, known as structural models, demonstrate that the
analysis of such data with standard statistical techniques (for
example, a Cox proportional hazards model with LTVV and risk
factors modeled as time-varying covariates) can lead to biased
results. More specifically, a bias can result when two condi-
tions occur: first, there is a measured time-dependent risk fac-
tor for survival that also predicts subsequent exposure to
LTVV, and second, past LTVV exposure affects the subse-
quent level of the risk factor. Within the ICAP study, these con-
ditions may be met for important time-varying risk factors, such
as organ failure and lung compliance, which may be associ-
ated with both death and compliance with LTVV while also
being associated with future levels of these exposures. To
avoid such bias in the statistical analysis, we plan to use struc-
tural models to estimate the causal effect of LTVV on mortality.
Additional analyses of LTVV will include assessing its casual
effect on functional status and quality of life. Because these
outcomes can be assessed only in survivors, the analysis of
functional status and quality of life, at a specified time point
after enrollment, is complicated by the high mortality rates of
critically ill patients [38]. An analysis that restricts the study
population to observed survivors can suggest a treatment
effect simply because the type of patients who survive differ
between treatment regimes. Recently developed statistical
methods that address this survivor bias [38-40] will be
extended to accommodate dynamic, time-varying treatments.
Secondary analyses in the ICAP study will examine the impact
of ICU exposures, other than LTVV, on long-term outcomes
including mortality, organ impairment, functional status, and
quality of life. Of particular interest are exposures previously
shown to affect short-term outcomes, including delirium [26],
sedative use [41], ICU organizational characteristics [18,42],
and tight glucose control with intravenous insulin therapy [43].
In addition, there are many other unanswered clinical ques-
tions that the ICAP study may inform, such as the association
between the dose and duration of use of steroids, and func-
tional status. The relationships between these exposures and
long-term outcomes in ALI/ARDS survivors currently remain
unclear, as do these exposures' relevant mechanisms of
Table 5
Retention strategies in the Improving Care of ALI Patients (ICAP) study
During inpatient stay
1. Describe the frequency, duration, and number of follow-up visits to potential participants
2. Collect comprehensive contact information (for example, address, multiple telephone numbers for patient and two or more contacts) for 
participant tracking
3. Visit the participant frequently, offering to answer any questions
4. Provide a business card before discharge and encourage the participant to call with questions
After discharge
1. Call the participant within 4 days of discharge to verify location and confirm health status
2. Send a letter and refrigerator magnet (with study logo and phone number) within 2 weeks of discharge
3. Call the participant 1 month after discharge to confirm health status and remind him/her about the ICAP study
Follow-up visits
1. Phone and mail (if necessary) the participant to schedule a follow-up visit at least 1 month in advance
2. Mail a confirmation letter with relevant instructions 2 weeks before the appointment
3. Phone the participant to remind him/her of the appointment 1 day before visit
4. Greet the participant at hospital entrance and accompany him/her throughout all stages and locations of the follow-up visit
5. Provide meal voucher and free parking or taxi service for the appointment
6. Mail the participant a handwritten thank-you note within 1 week after the appointment
Ongoing retention
1. Confirm contact information by phone or mail 18 months after ALI/ARDS diagnosis (for example, between 1-year and 2-year appointment)
2. Mail all patients an annual study newsletter
3. Mail each participant an annual birthday card, signed by all study staff
ALI, acute lung injury; ARDS, acute respiratory distress syndrome.Page 7 of 11
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effect of characterizing the exposure 'dose' as cumulative (for
example, total exposure during ICU stay), maximum/minimum
(highest or lowest value attained during ICU stay), or propor-
tional (percentage of ICU stay greater than a threshold). Ulti-
mately, these secondary analyses seek to extend the results of
previous studies and generate new hypotheses about how
existing clinical practices affect long-term patient outcomes.
Sample size
On the basis of the actual incidence of ALI/ARDS observed at
the participating hospitals during a previous randomized trial
[4], the ICAP study seeks to enroll 520 patients during its 2-
year enrollment period. With this sample size, the ICAP study
would be the largest existing prospective cohort study of long-
term outcomes in ALI/ARDS survivors [16] – significantly
larger than the largest previous study, which enrolled 107 sur-
vivors [44].
Because there are no available methods for computing power
or sample size for the statistical methods described above, we
estimated statistical power for the ICAP study with conven-
tional methods. On the basis of preliminary data regarding the
short-term mortality rates of ALI/ARDS patients in the ICAP
study and long-term mortality rates observed in previous stud-
ies [8,45], we expect that 50% of patients receiving more than
the median level of LTVV will die within two years of ALI/ARDS
diagnosis. Under these assumptions, the ICAP study has 86%
power to detect a relative hazard of 0.7 for 2-year mortality,
comparing equal-sized groups of patients receiving a higher
versus a lower proportion of LTVV (two-tailed α = 0.05). How-
ever, this calculation does not consider that the treatment
groups may be unbalanced with regard to confounding factors
for patient mortality. To address this deficiency, we conducted
a simulation to assess whether 520 patients, using an analysis
that accounts for confounding, would be adequate to detect a
30% relative reduction in mortality at two years. The majority
of the simulation scenarios yielded a power of more than 70%.
The benefit of the ICAP study's proposed sample size, in com-
parison with previous studies of ALI/ARDS survivors, is most
apparent when analyzing other patient outcomes. For example,
one important secondary outcome is the physical functioning
domain of the SF-36 quality of life survey. Physical functioning
has the greatest precision (for example, it reflects the greatest
number of response categories) of the eight SF-36 domains
and clinically represents an important domain for understand-
ing the impact of ALI/ARDS [8]. Recent expert panels have
suggested that the minimum clinically important difference in
the SF-36 physical functioning domain for patients with
chronic pulmonary conditions is 10 points [46,47]. The power
of the ICAP study to detect a 10-point difference at 2-year fol-
low-up, comparing patients receiving a higher proportion of
LTVV with patients receiving a lower proportion, is much
greater than in previous studies of ALI/ARDS survivors that
had sample sizes of less than 84 survivors [8,45,48-50] (Fig-
ure 2). Thus, the ICAP study will have sufficient power to
detect associations of clinical relevance that could not be ade-
quately investigated in earlier studies with smaller sample
sizes.
Discussion
The ICAP study is a multi-site, prospective cohort study that
seeks to evaluate the impact of ALI/ARDS, LTVV and other
aspects of ICU care on a variety of important long-term out-
comes. Whereas previous studies have measured long-term
outcomes in ALI/ARDS survivors, the ICAP study is distin-
guished by its larger sample size and its comprehensive meas-
urement of many ICU exposures and outcomes that have not
been adequately investigated in this patient population. Build-
ing on these strengths allows the ICAP study to evaluate the
impact, and associated mechanisms of action, of ICU thera-
pies on longer-term patient outcomes, and to generate hypoth-
eses for future research. Ultimately, the ICAP study seeks to
inform clinicians about the long-term effects of ALI/ARDS and
ICU therapies, so as to facilitate change in clinical practice and
improve outcomes for ALI/ARDS patients.
The ICAP study has potential limitations. First, because partic-
ipants are not randomly assigned to the ICU therapies under
investigation, the ICAP study is subject to 'confounding by
indication', [51] in that patients receiving certain therapies may
be systematically different from those not receiving the thera-
pies. If these differences are associated with the outcomes of
interest, the study results may be biased. The ICAP study's
comprehensive collection of exposure variables helps to miti-
gate this potential bias by enabling study investigators to
adjust for any measured factor found to predict the use of each
Figure 2
Power to detect a difference in physical functioning domain at 2 years in ALI survivors
in ALI survivors. Compares the projected power of the Improving Care 
of ALI Patients (ICAP) study with that of a hypothetical cohort study 
with a sample size of 80 acute lung injury/acute respiratory distress 
syndrome (ALI/ARDS) survivors [16], assuming a standard deviation of 
29 points in the SF-36 physical functioning quality of life domain [8], 
50% mortality in the ICAP study patient group receiving more frequent 
lower tidal volume ventilation (LTVV), a relative hazard of 0.7 for mortal-
ity comparing higher with lower frequency of LTVV, 10% additional 
losses to follow-up in both ICAP patient groups, and a two-sided type I 
error (α) of 0.05. ALI, acute lung injury.Page 8 of 11
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factors may be unknown or unmeasured, resulting in residual
confounding and bias. Second, despite frequent data collec-
tion, the ICAP study cannot fully capture the time-dependent
variation of dynamic exposures of ICU clinical management.
For example, ventilation parameters may change multiple times
per day, but could be measured only twice daily in the ICAP
study because of the associated data collection burden. Third,
although drawn from 11 different ICUs, all four study hospitals
are teaching and referral centers in a single city; thus, the
ICAP study results may not generalize to ALI/ARDS survivors
in other settings.
These limitations suggest several directions for future studies.
First, the design of future randomized trials of novel therapies
for ALI/ARDS should include the assessment of longer-term
outcomes, including quality of life [11,12]. Second, additional
methodological research should investigate the optimal data
collection instruments, measurement frequencies, and analytic
approaches for studying complex, time-varying exposures of
ICU clinical management and patient outcomes. Such
research would help to establish common measurement strat-
egies that could be used in future critical care research.
Finally, additional observational studies should be conducted
to assess the generalizability of findings from the ICAP study.
Conclusion
The ICAP study is a prospective cohort study that seeks to
provide new knowledge about the association of ALI/ARDS,
LTVV, and other aspects of ICU care with longer-term patient
outcomes. Strengths of the study include comprehensive
measurement of relevant exposures and outcomes, extensive
cohort retention strategies, novel analytic techniques, and a
relatively large projected sample size. Results from the ICAP
study should help to improve the care and long-term outcomes
of ALI/ARDS patients.
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